Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Insulin lispro Sanofi®
Insulin Lispro SAR342434 · 1 trial · 1 indication
Maximum Insulin (INS) concentration
Area under INS concentration time curve from 0 to last measurable concentration -
| Arm | Type | Description |
|---|---|---|
| Test (T) | EXPERIMENTAL | Insulin Lispro (SAR342434), 200 Units/ml, single dose on day 1 of each period |
| Reference (R) | ACTIVE_COMPARATOR | Insulin Lispro Sanofi® ,100 Units/ml, single dose on day 1 of each period |
| Name | Type | Description |
|---|---|---|
| Insulin Lispro SAR342434 | DRUG | Pharmaceutical form:solution for injection Route of administration: subcutaneous |
Inclusion criteria : * Male or female patients, between 18 and 64 years of age, inclusive, with diabetes mellitus type 1 for more than one year * Total insulin dose of \<1.0 U/kg/day * Fasting serum C-peptide \<0.30 nmol/L at screening * Glycohemoglobin (HbA1c) ≤75 mmol/mol (≤9%) at screening * Sta...
Top 10 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Tirzepatide, Baricitinib, LY4057996, Insulin Lispro |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Insulin icodec, Insulin aspart, NNC0194-0499, Semaglutide, NNC0497-0040 |
| Sanofi SA Sponsored ADR | SNY | 12 | PHASE3 | teplizumab/mL, Brivekimig, Frexalimab, Insulin |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | VX-880, VX-017, VX-264 |
| vTv Therapeutics, Inc. Class A | VTVT | 2 | PHASE3 | Cadisegliatin |
| SAB Biotherapeutics, Inc. | SABS | 1 | PHASE2 | SAB-142 |
| MannKind Corporation | MNKD | 2 | PHASE2 | Technosphere Insulin |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201 |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh | IMCR | 1 | PHASE1 | IMC-S118AI |
| Sana Biotechnology, Inc. | SANA | 1 | EARLY_PHASE1 | UP421 |
Insulin Lispro SAR342434 is an investigational insulin lispro formulation developed by Sanofi for the treatment of Type 1 Diabetes. It is a small molecule that acts as an agonist at the insulin receptor (INSR). The program has been studied in a Phase 1 bioequivalence trial comparing two different strength formulations.
Insulin Lispro SAR342434 is being developed for use in Type 1 Diabetes, where it is intended to provide insulin replacement therapy. It is an insulin receptor agonist. The only clinical study to date evaluated its use in patients with Type 1 Diabetes, not in healthy volunteers.
Insulin Lispro SAR342434 targets the insulin receptor, INSR, and acts as an agonist at that receptor. By activating INSR, it is designed to mimic the metabolic actions of endogenous insulin. This mechanism underlies its development for Type 1 Diabetes.
Insulin Lispro SAR342434 is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the clinical program for this insulin lispro formulation. The asset is identified in public chemical databases under the ChEMBL ID CHEMBL1201631.
Insulin Lispro SAR342434 is in Phase 1 clinical development. It is an investigational product and has not been approved by the FDA. The program's single Phase 1 trial has been completed, and no active trials are currently listed for this asset.
Insulin Lispro SAR342434 has been studied in one completed Phase 1 trial, NCT03903016, titled a bioequivalence study comparing two different strength formulations of insulin lispro in patients with Type 1 Diabetes. The trial enrolled 90 participants in Germany, was randomized, double blind, and active controlled.